ArticleInternational journal of preventive medicine2012
Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants.
Article in International journal of preventive medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 43 citations in OpenAlex.
- The rise of reducing reagent-resistant TfR1 dimer marks ferroptosis.Nature cell biology · 2026Article
- The interplay mechanisms between gut microbiota and ferroptosis in inflammatory bowel disease.Frontiers in immunology · 2026Review
- Ferroptosis in Autoimmune Diseases: Research Advances and Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Integrative Multi-Omics Reveals the Anti-Colitis Mechanisms ofNutrients · 2025Article
- Fibroblast lipid metabolism through ACSL4 regulates epithelial sensitivity to ferroptosis in IBD.Nature metabolism · 2025Article
- The metabolites of gut microbiota: their role in ferroptosis in inflammatory bowel disease.European journal of medical research · 2025Review
- Xiaoyao Pill alleviates ulcerative colitis by inhibiting ferroptosis of enterocytes via activating Nrf2/Gpx4 signaling pathway.Frontiers in pharmacology · 2025Article
- Protective role of seleno-amino acid against IBD via ferroptosis inhibition in enteral nutrition therapy.iScience · 2024Article
- GPX4 restricts ferroptosis of NKp46Cell death & disease · 2024Article
- Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatment.Acta pharmaceutica Sinica. B · 2024Review
- SELENOI Functions as a Key Modulator of Ferroptosis Pathway in Colitis and Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The important role of ferroptosis in inflammatory bowel disease.Frontiers in medicine · 2024Review
- Ferroptosis: a new mechanism of traditional Chinese medicine for treating ulcerative colitis.Frontiers in pharmacology · 2024Review
- Ferroptosis and its impact on common diseases.PeerJ · 2024Review
- Reactive Oxygen Species and Ferroptosis at the Nexus of Inflammation and Colon Cancer.Antioxidants & redox signaling · 2023Review
- Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease (Review).International journal of molecular medicine · 2023Review
- Identification of ferroptosis-related genes in ulcerative colitis: a diagnostic model with machine learning.Annals of translational medicine · 2023Article
- Ferroptosis as a therapeutic target for inflammation-related intestinal diseases.Frontiers in pharmacology · 2023Review
- Iron Deprivation by Oral Deferoxamine Application Alleviates Acute Campylobacteriosis in a Clinical MurineBiomolecules · 2022Article
- Endometrial Regenerative Cell-Derived Exosomes Attenuate Experimental Colitis through Downregulation of Intestine Ferroptosis.Stem cells international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIron chelators, such as maltol and kojic acid, have antioxidant and anti-inflammatory properties. They may have beneficial effects on inflammatory bowel disease (IBD) because iron can develop and aggravate inflammation in IBD. In the present study, the effect of selected iron chelators and anti-oxidants were evaluated on a model of trinitrobenzene sulfonic acid (TNBS)-induced colitis.
methodsColitis was induced with instillation of 75 mg/kg TNBS in 0.25 ml ethanol 50% via the anus in fasted male Wistar rats. The animals were assigned randomly to 12 groups (n = 6) and treated once daily, started 2 hours before colitis induction, with normal saline (5 ml/kg), maltol (70, 140, 280 mg/kg), kojic acid (75, 150, 300 mg/kg), vitamin E (400 mg/kg), deferiprone (L1) (150 mg/kg) and prednisolone (4 mg/kg) orally and deferoxamine (50 mg/kg) intraperitoneally for 5 days. In the sixth day, rats were scarified and colon tissues were assessed macroscopically and pathologically.
resultsMaltol (280 mg/kg) was able to reduce colon weight / length ratio, ulcer index and total colitis index similar to prednisolone, deferoxamine and deferiprone as positive controls. However, kojic acid and vitamin E could not significantly alleviate macroscopic and/or pathologic features of inflammation in comparison to normal saline.
conclusionsMaltol with the highest test dose was capable to protect against experimentally induced colitis. Kojic acid and vitamin E were not effective in this animal model of colon inflammation. More detailed studies are warranted to explore the mechanisms involved in anti-colitic property of maltol and to explain ineffectiveness of kojic acid and vitamin E.
Indexed as
Identifiers
22826760PMC3399289W1537170429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.